Lorlatinib (Lorviqua) is a third-generation dual-target inhibitor of ALK/ROS1 and has become an important treatment option for patients with ALK-positive non-small cell lung cancer (NSCLC).

What Are the Purchase Channels for Lorlatinib (Lorviqua)?

Overseas Purchase

(1) Patients can choose to consult and purchase the drug at hospital pharmacies or licensed pharmacies in countries or regions where lorlatinib has been launched.

(2) Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase through Medical Service Institutions

(1) Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

(2) These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Lorlatinib (Lorviqua)

Strictly Follow Medical Guidance

(1) According to the instructions approved by the U.S. FDA, the standard dose of lorlatinib is 100 mg orally once daily. The tablets must be swallowed whole and should not be chewed, crushed, or split.

(2) In case of a missed dose, if more than 4 hours are left before the next scheduled dose, the missed dose can be supplemented; otherwise, the dose should be skipped.

Be Alert to Drug Interactions

(1) Concomitant use of lorlatinib with strong CYP3A inducers (such as rifampicin, phenytoin, etc.) may trigger a risk of severe hepatotoxicity.

(2) Therefore, before purchasing the drug, patients need to fully inform their doctors of all medications they are taking, including prescription drugs, over-the-counter drugs, and herbal preparations.

Standardize Drug Storage and Management

The drug should be stored at room temperature (20°C-25°C), away from direct sunlight, high temperature, or humid environments to ensure the stability of the drug.

Verify Drug Suitability

It is necessary to confirm whether the drug specification meets the treatment needs (there are currently two specifications: 25mg and 100mg) and check the information of the manufacturer (Pfizer Pharmaceuticals).

Identify Potential Medication Risks

(1) Common adverse reactions include edema (56%), peripheral neuropathy (44%), cognitive effects (28%), and hyperlipidemia (the incidence of elevated cholesterol exceeds 90%).

(2) Patients need to understand the relevant symptoms and report them to their doctors in a timely manner.

Authenticity Identification of Lorlatinib (Lorviqua)

Packaging Information Verification

(1) Carefully check the printing quality of the packaging box, as well as key information such as the enterprise logo (Pfizer), product batch number, and approval number.

(2) The packaging of genuine drugs should have clear printing and complete information without omissions.

Anti-Counterfeiting Feature Identification

(1) Confirm the drug's identity through the official anti-counterfeiting inquiry system (such as QR code verification).

(2) At the same time, check whether the marking information on the tablets is consistent with the description in the instruction manual.